Canaccord lowered the firm’s price target on Adicet Bio to $19 from $21 and keeps a Buy rating on the shares. The firm noted the company is shifting its focus to autoimmune diseases and lowered its target to reflect a delayed pivotal trial.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACET:
- Adicet Bio price target lowered to $6 from $10 at BTIG
- Adicet Bio price target lowered to $21 from $28 at Canaccord
- Adicet Bio reports Q3 EPS ($1.16), consensus (74c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue